Evidence map›Paper›PMID 34232206›Full record

ArticleMedicine2021

Microvascular invasion may be the determining factor in selecting TACE as the initial treatment in patients with hepatocellular carcinoma.

Joonho Jeong, Jung Gu Park, Kwang Ill Seo, Ji Hyun Ahn, Jae Chun Park, Byung Cheol Yun, Sang Uk Lee, Jin Wook Lee, Jong Hyouk Yun

Abstract read
In one paragraph

Article in Medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Joonho JeongDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Ulsan University Hospital, Ulsan University College of Medicine, Ulsan.
Jung Gu ParkDepartment of Radiology.ORCID 0000-0002-1229-5745
Kwang Ill SeoDivision of Hepatology, Department of Internal Medicine.
Ji Hyun AhnDepartment of Pathology, Kosin University College of Medicine, Busan, Korea.
Jae Chun ParkDepartment of Radiology.
Byung Cheol YunDivision of Hepatology, Department of Internal Medicine.
Sang Uk LeeDivision of Hepatology, Department of Internal Medicine.
Jin Wook LeeDivision of Hepatology, Department of Internal Medicine.
Jong Hyouk YunDepartment of Radiology.

Funding

National Research Foundation of Korea. 2019M3E5D1A02070868
6 · The paper itself

Abstract

abstractThe aim of this study was to investigate factors affecting tumor necrosis with transcatheter arterial chemoembolization (TACE). Factors associated with early hepatocellular carcinoma recurrence after curative hepatectomy were also evaluated.Data of 51 patients who underwent surgery after a single session of TACE at a single university hospital were retrospectively analyzed. Factors that might affect tumor necrosis were determined by evaluating the TACE approach and by analyzing computed tomography and TACE findings, pathologic reports, and laboratory findings.In univariate analysis, microvascular invasion (MVI), radiological capsule appearance on the computed tomography, chronic hepatitis B, diabetes mellitus and serum albumin, MVI were significantly associated with tumor necrosis by TACE (P < .02). In multivariate analysis, MVI was the only statistically significant factor in TACE-induced tumor necrosis (P = .001). In univariate and multivariate analysis, MVI was the strongest factor for recurrence-free survival rate within 2 years (P = .008, P = .002).MVI could be a crucial factor in determining TACE as an initial treatment for hepatocellular carcinoma. MVI is also a strong indicator of recurrence within 2 years after curative hepatic resection.

Indexed as

Carcinoma, HepatocellularChemoembolization, TherapeuticFemaleHepatectomyHumansLiver NeoplasmsMaleMicrovesselsMiddle AgedNeoplasm InvasivenessRetrospective Studies

Identifiers

PMID34232206
PMCPMC8270609

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.